Equities
  • Price (EUR)0.3564
  • Today's Change-0.01 / -2.73%
  • Shares traded0.00
  • 1 Year change-72.37%
  • Beta--
Data delayed at least 15 minutes, as of Dec 02 2022 07:01 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Cybin Inc. is a Canada-based biotechnology company. The Company is focused on progressing Psychedelics to therapeutics by engineering drug discovery platforms, drug delivery systems, formulation approaches and treatment regimens for mental health disorders. Across the various research and development programs, the Company is researching and developing an array of synthetic psychedelic active pharmaceutical ingredients (API) intended to be delivered through drug delivery systems, including sublingual films1, orally disintegrating tablets (ODT)2, via inhalation and via intravenous (IV). Its drug programs include Depressive Disorder (CYB003), Alcohol Use Disorder (CYB003), Anxiety Disorders (CYB004) and Neuroinflammation (CYB005). The Company focuses on the clinical development path for CYB004, the Company's deuterated Phase 1 N,N-dimethyltryptamine (DMT) molecule, for the treatment of anxiety disorders. Its subsidiaries include Cybin Corp., Natures Journey Inc, and others.

  • Revenue in CAD (TTM)0.00
  • Net income in CAD-58.34m
  • Incorporated2016
  • Employees50.00
  • Location
    Cybin Inc100 King Street West, Suite 5600TORONTO M5X 1C9CanadaCAN
  • Phone+1 (604) 806-0626
  • Fax+1 (604) 806-0626
  • Websitehttps://www.cybin.com
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.